The September 5th episode of The Daily AI Show was a Friday wrap-up covering multiple AI stories. The hosts discussed OpenAI’s rumored LinkedIn competitor, Apple’s shift toward building its own AI-powered search for Siri, FDA approval of the first AI-designed drug for animal trials, industrial robotics, and other emerging AI developments.

Key Points Discussed

OpenAI plans to launch a job platform in 2026, potentially disrupting LinkedIn with AI-powered talent matching and broader ambitions in browsers, social media, CRMs, and office suites.

Apple is preparing to build its own AI search engine to replace Google as the default in Siri, partly due to new antitrust rulings. This comes as iPhone sales in India grow despite global challenges.

The FDA approved the first AI-designed cancer drug for animal trials, developed in 18 months instead of the usual 42, marking a breakthrough in faster, cheaper drug discovery.

Penn State researchers also developed an AI system using diffusion models to generate and refine peptide sequences, accelerating drug candidate selection.

Industrial robotics remains dominated by Japan and Europe, with Kuka, ABB, and Fanuc leading sectors like automotive and electronics. The discussion tied in how embodied AI could follow the same trajectory.

IBM and NASA created an AI model to predict large solar flares, helping protect against potential EMP-level disruptions to global infrastructure.

Meta is advancing Llama 5 and using Anthropic’s Claude Code internally, while exploring integration of external models like Google and OpenAI into its apps.

Discussion of Codex vs Claude Code highlighted rapid improvements in AI coding assistants, with expectations that Gemini 3 will intensify competition.

Timestamps & Topics

00:00:00 💡 Intro and topics preview

00:03:07 🍏 Apple’s AI search plans and Siri updates

00:07:10 📱 Apple’s India growth and iPhone pricing challenges

00:09:21 📱 Frustrations with Apple Intelligence integration

00:10:27 📱 Pixel 10 interest as an Apple alternative

00:12:00 👻 Snapchat’s staying power with younger generations

00:15:35 💊 FDA approval of AI-designed cancer drug for trials

00:19:54 🧪 Penn State’s AI diffusion model for peptide design

00:22:10 💉 Shortening the timeline for drug discovery and trials

00:24:22 🏢 OpenAI’s LinkedIn competitor and broader platform ambitions

00:26:30 🌐 OpenAI’s AI-powered web browser plans

00:27:54 📣 OpenAI’s prototype social media platform

00:28:23 📊 CRM proof of concept and Salesforce pressure

00:29:44 📑 OpenAI’s push toward an office suite competitor

00:30:13 💾 OpenAI and Broadcom’s $10B AI chip partnership

00:31:52 💰 OpenAI’s valuation trajectory and trillion-dollar potential

00:33:28 💸 Equity, stock options, and AI talent poaching

00:36:41 🤖 Industrial robotics market breakdown (Japan, Germany, Switzerland, China)

00:39:35 🎢 Kuka arms in automotive and theme park rides

00:43:30 🌞 IBM and NASA’s AI solar flare prediction model

00:45:09 🦙 Meta’s Llama 5, model integrations, and use of Claude Code

00:47:20 💻 Codex vs Gemini 2.5 Pro in coding tasks

00:48:13 📚 Notebook LM adoption and AI in education

00:49:35 🗞️ Wrap up, newsletter, and community invite

The Daily AI Show Co-Hosts: Andy Halliday, Beth Lyons, Brian Maucere, Eran Malloch, Jyunmi Hatcher, and Karl Yeh

OpenAI, AI Drugs, & Siri's Fate (Ep. 545)

The Daily AI Show